title: [Role of pharmacogenetics in chemotherapy of colorectal cancers].
abstract: METHODS
  Clinical implications associated with polymorphisms in drug-metabolizing genes involved in the chemotherapy of colorectal cancers (5-flurorouracil, oxaliplatin and irinotecan) are reviewed.
  
  
  BACKGROUND
  Treatments of colorectal cancers have been greatly improved last years but patients respond differently to identical medication. Genetic polymorphisms are one of the major causes of these individual responses to drugs associated with sometimes severe adverse effects. Pharmacogenetics is based on all polymorphisms that determine genetic human diversity associated with variable response to anticancer drugs.
  
  
  CONCLUSIONS
  Morbidity and mortality related to toxicity or inefficacy of these drugs could be reduced by analyzing the pharmacogenetic profile of patients before treatment. Results should be integrated in protocols for monitoring and assessment the dosage of drugs.
authors.affiliation: Laboratoire de biochimie, toxicologie et pharmacologie cliniques, HIA Bégin, 69, avenue de Paris, 94163 Saint-Mandé cedex, France. hiabegin.biochimie@worldonline.fr
authors.forename: F
authors.initials: F
authors.lastname: Ceppa
authors.forename: E
authors.initials: E
authors.lastname: Fontan
authors.forename: S
authors.initials: S
authors.lastname: Cremades
authors.forename: R
authors.initials: R
authors.lastname: Bihannic
authors.forename: A
authors.initials: A
authors.lastname: Bousquet
authors.forename: L
authors.initials: L
authors.lastname: Beauvillain
authors.forename: P
authors.initials: P
authors.lastname: Burnat
mesh_terms: D000110:Acetylcholinesterase / Q000235:genetics; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002091:Butyrylcholinesterase / Q000235:genetics; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics; D006801:Humans; D000077146:Irinotecan; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D009944:Organoplatinum Compounds / Q000009:adverse effects; D000077150:Oxaliplatin; D010597:Pharmacogenetics / Q000379:methods*; D011110:Polymorphism, Genetic
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D042943:Dihydrouracil Dehydrogenase (NADP); D042965:Methylenetetrahydrofolate Reductase (NADPH2); D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase; D002166:Camptothecin